New York, September 30, 2024 - PRISM MarketView - BrainsWay (NASDAQ: BWAY) has entered into a private investment financing deal with Valor Equity Partners, a firm renowned for supporting industry leaders such as SpaceX, Tesla, Neuralink, and Harmony Biosciences. This investment brings in gross proceeds of approximately $20 million and will drive BrainsWay’s strategic initiatives, including market expansion, data analysis enhancements, R&D development, and broader access to its Deep TMS™ technology. Valor will also have the right to nominate members to BrainsWay’s board. The $9.51 per ADS purchase price represents a 20% premium over the 30-day average.
“With this transaction, we will be better positioned to accelerate the growth of our business by tapping into new markets and new revenue channels, including customer types and commercial partnerships. During the past year, we have received several inbound requests from leading investment groups interested in investing in BrainsWay.”
Ami Boehm, the Company’s Chairman of the Board
BrainsWay is currently leading the PRISM Emerging Mental Health Index, with shares up 12%.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities